Efficacy relevance of PD-L1 expression on circulating tumor cells in metastatic breast cancer patients treated with anti-PD-1 immunotherapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy relevance of PD-L1 expression on circulating tumor cells in metastatic breast cancer patients treated with anti-PD-1 immunotherapy

Published:2023-05-25 Issue:2 Volume:200 Page:281-291
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Zhou Ying,Zhou Jinmei,Hao Xiaopeng,Shi Haoyuan,Li Xuejie,Wang Anqi,Hu Zhiyuan^ORCID,Yang Yanlian,Jiang Zefei,Wang Tao^ORCID

Funder

Research Foundation for Advanced Talents of Fujian Medical University

Beijing Natural Science Foundation

Strategic Priority Research Program of Chinese Academy of Sciences

the National Natural Science Foundation of China

the Natural Science Foundation of Fujian Province

CAS-JSPS

Science and Technology Service Network Initiative of the Chinese Academy of Sciences

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s10549-023-06972-6.pdf

Reference52 articles.

1. Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics. CA Cancer J Clin 72(1):7–33. https://doi.org/10.3322/caac.21708

2. Zou Y, Zou X, Zheng S, Tang H, Zhang L, Liu P, Xie X (2020) Efficacy and predictive factors of immune checkpoint inhibitors in metastatic breast cancer: a systematic review and meta-analysis. Ther Adv Med Oncol 12:1758835920940928. https://doi.org/10.1177/1758835920940928

3. Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, Peto R, Pritchard KI, Bergh J, Dowsett M, Hayes DF (2017) 20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med 377(19):1836–1846. https://doi.org/10.1056/NEJMoa1701830

4. Salvo EM, Ramirez AO, Cueto J, Law EH, Situ A, Cameron C, Samjoo IA (2021) Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: a systematic review and meta-analysis. Breast 57:5–17. https://doi.org/10.1016/j.breast.2021.02.009

5. Bonotto M, Gerratana L, Poletto E, Driol P, Giangreco M, Russo S, Minisini AM, Andreetta C, Mansutti M, Pisa FE, Fasola G, Puglisi F (2014) Measures of outcome in metastatic breast cancer: insights from a real-world scenario. Oncologist 19(6):608–615. https://doi.org/10.1634/theoncologist.2014-0002

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors – a biomarker analysis of the ALICE and ICON trials;Molecular Oncology;2024-07-08

2. Structural Transformation Through a Multi-vector Geo-economic Governance? BRI and Upgrading of the Uzbek Gas Industry;The European Journal of Development Research;2024-06

3. Cellular residual disease (CRD) in early breast cancer –Expanding the concept of minimal residual disease monitoring?;The Journal of Liquid Biopsy;2024-03

4. Cost-effectiveness analysis of toripalimab for metastatic or recurrent triple-negative breast cancer;Frontiers in Oncology;2024-01-18

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3